{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T12:08:44Z","timestamp":1772971724358,"version":"3.50.1"},"reference-count":16,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Erythropoietin receptor agonists (ERAs) are drugs acting on the early erythropoietic stages developed to treat anemia and other erythropoiesis disease and are prohibited by the World Anti\u2010Doping Agency (WADA). As an alternative to ERAs, a new drug, belonging to the transforming growth factor\u2010b inhibitors family, was recently developed to treat diseases linked to ineffective erythropoiesis. This drug, named as Luspatercept (Reblozyl\u00ae), is acting on the later stages of erythropoiesis to promote erythrocytes. This drug might be used by cheating athletes either independently or in combination with ERAs. Indeed, it was shown that Luspatercept and recombinant erythropoietin (rEPO) can act synergistically to increase red blood cells production, potentially allowing the use of lower doses for an efficient effect. Our aim was to find a way to combine the detection of ERAs and Luspatercept without impacting the sensitivity and specificity of ERAs detection from the current techniques implemented in antidoping laboratories and to reduce the time of analysis and total sample volume needed. Magnetic beads coated with antibodies were preferred for IP of samples for its potential multiplexing. Then, the following steps of the method were selected considering that SAR\/SDS\u2010PAGE are the electrophoretic methods authorized for initial testing procedure by WADA and that biotinylated primary antibodies used for the immunodetection results in the best sensitivity and specificity and is time saving. The method developed in this work for the combined detection of agents affecting erythropoiesis (AAEs) showed specificity, sensitivity, and robustness and is easily and quickly implementable to all antidoping laboratories.<\/jats:p>","DOI":"10.1002\/dta.3136","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T02:59:15Z","timestamp":1627959555000},"page":"1791-1796","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Multiplexed detection of agents affecting erythropoiesis (AAEs) and overall strategy for optimizing initial testing procedure"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3330-2884","authenticated-orcid":false,"given":"Laurent","family":"Martin","sequence":"first","affiliation":[{"name":"D\u00e9partement des Analyses Agence Fran\u00e7aise de Lutte contre le Dopage (AFLD)  Ch\u00e2tenay\u2010Malabry France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus","family":"Ericsson","sequence":"additional","affiliation":[{"name":"D\u00e9partement des Analyses Agence Fran\u00e7aise de Lutte contre le Dopage (AFLD)  Ch\u00e2tenay\u2010Malabry France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2670-6939","authenticated-orcid":false,"given":"Alexandre","family":"Marchand","sequence":"additional","affiliation":[{"name":"D\u00e9partement des Analyses Agence Fran\u00e7aise de Lutte contre le Dopage (AFLD)  Ch\u00e2tenay\u2010Malabry France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,8,19]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/35015164"},{"key":"e_1_2_5_3_1","first-page":"1","article-title":"An optimized SDS\u2010PAGE protocol with a new blotting system for the initial testing procedure of ESAs in doping control","author":"Martin L","year":"2020","journal-title":"Drug Test Anal"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1915"},{"key":"e_1_2_5_5_1","unstructured":"https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/td2021epo_final_eng_v_2.0.pdf"},{"issue":"5","key":"e_1_2_5_6_1","first-page":"586","article-title":"Sotatercept, a soluble activin receptor type 2A IgG\u2010Fc fusion protein for the treatment of anemia and bone loss","volume":"12","author":"Raje N","year":"2010","journal-title":"Curr Opin Mol Ther"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3512"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01251-5"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2476"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2376"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2302"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2513"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1579"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2185"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1361"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23732"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-2697(02)00407-4"}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.3136","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/dta.3136","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.3136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T20:49:23Z","timestamp":1760388563000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.3136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,19]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1002\/dta.3136"],"URL":"https:\/\/doi.org\/10.1002\/dta.3136","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"value":"1942-7603","type":"print"},{"value":"1942-7611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,19]]},"assertion":[{"value":"2021-06-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}